Latest Research Development News

Careteq Limited reported a disciplined operating cash flow in Q2 FY26 with strong growth in its Embedded Health Solutions segment and ongoing resolution of an ATO tax incentive dispute.

IODM Limited has reported a standout Q2 FY26 with record cash receipts driven by strong UK education sector growth and strategic board renewal.

Cycliq Group Ltd reported a 21% decline in customer receipts for Q2 FY2026, offset by a solid net operating cash inflow and a strong Black Friday campaign that generated $1.3 million in gross revenue.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

James Hardie Industries is set to close its Fontana and Summerville manufacturing plants, consolidating production to boost efficiency and cut costs by $25 million annually starting next fiscal year.

Clinuvel Pharmaceuticals has initiated dosing in a preclinical study of its novel controlled-release injectable peptide platform, VLRX-L, aiming to enhance drug delivery for melanocortin-based therapies. Preliminary results are expected in the second half of 2026.

Aeeris Ltd has received a $506,992.50 refundable R&D tax incentive for FY25, fueling advancements in its proprietary Australian Weather And Risk Environment (AWARE) system and AI-driven forecasting tools.

Unith Ltd has strengthened its financial footing by securing a $1 million unsecured facility and receiving initial R&D tax refunds from Spain, validating its advanced AI platform and supporting its growth ambitions.

Fortifai Limited has acquired an exclusive license to Nol8, a breakthrough real-time data processing technology developed by the Technion. This acquisition positions Fortifai to revolutionize data handling across gaming, AI, finance, and cybersecurity sectors.

Algorae Pharmaceuticals has secured a $384,466 cash refund from the Australian Taxation Office, reinforcing its financial position to advance AI-driven drug discovery programs.

CLINUVEL Pharmaceuticals is significantly expanding its VALLAURIX RD&I Centre in Singapore with a five-year strategic investment, aiming to become a global leader in advanced peptide drug delivery.